Valeant Pharmaceuticals Intl Inc news

   Watch this stock
Showing stories 1 - 10 of about 130   

Articles published

VRX 128.77 -1.61 (-1.23%)
price chart
Why Valeant Pharmaceuticals Intl Inc. and Allergan Inc. Would Be Better Together
Valeant Pharmaceuticals Intl Inc.(TSX: VRX)(NYSE: VRX) and Pershing Square Capital Management LP submitted a hostile bid for Allergan Inc. (NYSE: AGN) months ago, but any potential for a deal appeared dead after both sides exchanged barbs.
Allergan Ups Earnings Guidance Amid Takeover Battle With Valeant  Bidness ETC
Allergan, Inc. Stock Jumps After Big Guidance Increase  ValueWalk
Related articles »  
2 Reasons to Avoid Valeant Pharmaceuticals Intl Inc, and 1 Stock to Buy Instead
In Canada, few companies are able to seriously compete on the global stage. But Valeant Pharmaceuticals Intl Inc (TSX: VRX)(NYSE: VRX) is one of them, and has become one of the country's big success stories.
Actavis plans new merger approach for Allergan Inc as Valeant Pharmaceuticals ...
Allergan, which has repeatedly rejected offers from Valeant Pharmaceuticals International Inc, would consider a takeover proposal that values the company at above $200 per share, some of these people said.
Latest Strategy in Valeant Pharmaceuticals Intl Inc (VRX) -Pershing ...  StockWise Daily
Exclusive: Actavis plans new merger approach for Allergan - sources  Reuters
Related articles »  
Valeant Pharmaceuticals To Announce 2014 Third Quarter Results On October ...
LAVAL, Quebec, Oct. 15, 2014 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Monday, October 20, 2014 at 8:00 ...
Related articles »  
Valeant Shows Intent To Raise Bid For Allergan
Valeant Pharmaceuticals Intl Inc (VRX) said yesterday that it will consider raising its bid to buy Allergan, Inc. (AGN) and will not back off from pursuing the company before Allergan holds the special shareholder meeting scheduled to take place on ...
Valeant Pharmaceuticals Quarterly Earnings Analysis (VRX)
Valeant Pharmaceuticals International just reported its preliminary financial results based on which we provide a unique corporate earnings release based analysis of its performance.
Related articles »  
Buzz Stocks: Microsoft Corporation, Family Dollar Stores, Inc., and Valeant ...
Bolstering the stock is a stronger-than-expected earnings report and forward guidance, and Valeant Pharmaceuticals Intl Inc CEO's confession that the company is just waiting on the "appropriate time" to up its bid for Allergan, Inc. (NYSE:AGN). While ...
Valeant Pharmaceuticals Intl Earns "Buy" Rating from Aegis (VRX)
The stock has a consensus rating of Buy and an average price target of $148.56. Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a ...
Stocks in Focus - Valeant Pharmaceuticals Intl Inc (NYSE:VRX), VF Corp (NYSE ...  Street Newswire (registration)
Valeant Pharmaceuticals Intl Rating Reiterated by Jefferies Group (VRX)  Watch List News (press release)
Related articles »  
Jeffrey W. Ubben, CEO Of ValueAct Capital, Appointed To The Board Of Valeant ...
25, 2014 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today announced that its Board of Directors has appointed Jeffrey W. Ubben, Founder, Chief Executive Officer, and the Chief Investment Officer of ValueAct Capital, as a ...
Allergan Issues Statement Regarding Recent Valeant Correspondence  Businessweek
Related articles »  
Valeant Pharmaceuticals Intl Inc (VRX) Issues FY15 Earnings Guidance
Valeant Pharmaceuticals Intl logo Valeant Pharmaceuticals Intl Inc (NYSE:VRX) updated its FY15 earnings guidance on Monday.